A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

Lijoy Varghese (), Louise Talbot (), Andrea Govender (), Xu-Hao Zhang () and Bruce A. Mungall ()
Additional contact information
Lijoy Varghese: GSK Pte Ltd
Louise Talbot: GSK
Andrea Govender: GSK
Xu-Hao Zhang: GSK Pte Ltd
Bruce A. Mungall: GSK Pte Ltd

Applied Health Economics and Health Policy, 2018, vol. 16, issue 3, No 6, 345 pages

Abstract: Abstract Objectives Invasive pneumococcal disease (IPD), pneumonia and acute otitis media (AOM) still represent a significant medical burden in children

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-018-0387-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:16:y:2018:i:3:d:10.1007_s40258-018-0387-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-018-0387-5

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().